Roche has obtained two RNA-targeted drug programs for Alzheimer’s and Huntington’s diseases from Ionis Pharmaceuticals. The deal involves a $60 million upfront payment for the global exclusive rights, with further milestone payments and royalties possible. If approved, Roche will also handle clinical development, manufacturing, and commercialization of the treatments. This addition expands an existing partnership between the two firms, which began with developing an experimental Huntington’s treatment, tominersen. Moreover, this agreement indicates the ongoing growth in the Alzheimer’s research market. Ionis, on a successful run, recently announced the success of its Phase 3 trial for the rare disease therapy olezarsen.
To read more, click here.
[Source: MM+M, September 27th, 2023]